State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
State Key Laboratory of Biotherapy, Cancer Center, Sichuan University, Chengdu, China.
J Cell Physiol. 2020 Jul;235(7-8):5490-5500. doi: 10.1002/jcp.29551. Epub 2020 Feb 6.
Tumor microenvironment is known to play important roles in tumor progression. Many therapies, targeting the tumor microenvironment, are designed and applied in the clinic. One of these approaches is in situ antitumor therapy. This way, bacteria, antibodies, plasmid DNA, viruses, and cells are intratumorally delivered into the tumor site as "in-situ antitumor vaccine," which seeks to enhance immunogenicity and generate systemic T cell responses. In addition, this intratumoral therapy can alter the tumor microenvironment from immunosuppressive to immunostimulatory while limiting the risk of systemic exposure and associated toxicity. Contemporarily, promising preclinical results and some initial success in clinical trials have been obtained after intratumoral therapy.
肿瘤微环境在肿瘤进展中起着重要作用。许多针对肿瘤微环境的治疗方法被设计并应用于临床。其中一种方法是原位抗肿瘤治疗。通过这种方式，细菌、抗体、质粒 DNA、病毒和细胞被作为“原位抗肿瘤疫苗”瘤内递送到肿瘤部位，旨在增强免疫原性并产生全身性 T 细胞反应。此外，这种瘤内治疗可以改变肿瘤微环境，从免疫抑制转变为免疫刺激，同时限制全身暴露和相关毒性的风险。目前，瘤内治疗已经取得了有前景的临床前结果和一些初步的临床试验成功。
